Financings in Brief: Instrumentation Laboratory SpA
This article was originally published in The Gray Sheet
Executive Summary
Instrumentation Laboratory SpA: Grosses $37.5 mil. from initial public offering of American Depositary Shares completed on Oct. 31. About 3.1 mil. shares priced at $12 each were offered by the firm. An additional 2.2 mil. shares were offered by selling shareholders. Underwriters Salomon Brothers, Dillon, Read & Co and UBS Securities have an overallotment option for 804,733 additional shares. In conjunction with the public offering, the firm also is issuing 1.9 mil. ordinary shares "most of which are being purchased by the company's majority shareholder," the firm states. Net proceeds from the stock sales will be used to repay debt...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.